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Abstract
Background: The functional relevance of many of the recently detected JAK2 mutations, except
V617F and exon 12 mutants, in patients with chronic myeloproliferative neoplasia (MPN) has been
significantly overlooked. To explore atomic-level explanations of the possible mutational effects
from those overlooked mutants, we performed a set of molecular dynamics simulations on clinically
observed mutants, including newly discovered mutations (K539L, R564L, L579F, H587N, S591L,
H606Q, V617I, V617F, C618R, L624P, whole exon 14-deletion) and control mutants (V617C,
V617Y, K603Q/N667K).
Results:  Simulation results are consistent with all currently available clinical/experimental
evidence. The simulation-derived putative interface, not possibly obtained from static models,
between the kinase (JH1) and pseudokinase (JH2) domains of JAK2 provides a platform able to
explain the mutational effect for all mutants, including presumably benign control mutants, at the
atomic level.
Conclusion: The results and analysis provide structural bases for mutational mechanisms of JAK2,
may advance the understanding of JAK2 auto-regulation, and have the potential to lead to
therapeutic approaches. Together with recent mutation profiling results demonstrating the breadth
of clinically observed JAK2 mutations, our findings suggest that molecular testing/diagnostics of
JAK2 should extend beyond V617F and exon 12 mutations, and perhaps should encompass most
of the pseudo-kinase domain-coding region.
Background
Protein kinases play critical key roles in cellular signal
transduction and can be activated by either phosphoryla-
tion or interaction with other proteins or ligands [1-4].
However, surprisingly little is known about protein-pro-
tein interactions involved in kinase activation processes.
Scaffolds have been shown as allosteric regulators of
kinases; symmetrical dimers of kinases could be involved
in auto-phosphorylation regulation; and many protein
kinases may be regulated via N-lobe interactions. In many
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protein kinases, activity is regulated by the coupling
between the C-helix and regulatory domains [5-7]. In oth-
ers, the catalytic domains act as their own regulatory
regions [8,9]. Recently, the MAP2K MEK6 was demon-
strated to be auto-regulated via the formation of a sym-
metrical dimer [10].
Janus kinase 2 (JAK2) is a protein tyrosine kinase that
transduces cellular signals through the JAK-STAT path-
ways [11,12]. Deregulation of JAK2 is thought to be asso-
ciated with hematopoietic disorders and oncogenesis [13-
17], especially in patients with BCR-ABL-negative myelo-
proliferative neoplasms (MPNs) [18]. However, the regu-
lation mechanism of JAK2 remains elusive. Its kinase
domain, JH1, is likely negatively regulated [19,20] by the
adjacent pseudo-kinase domain, JH2, probably in a man-
ner similar to the mechanism of JAK3 regulation [21].
Although other kinase/pseudo-kinase systems have been
reported recently [22], the detailed interactions of JH1/
JH2 are not well-understood, owing to a lack of available
experimental structures. A theoretical structure model of
the whole JAK2 assembly has been built using homology
modeling methods and co-evolution data [23,24]. In this
model, the JH1 and JH2 domains face each other in an
anti-symmetrical way; that is, the JH1 N-lobe contacts the
JH2 C-lobe while the JH1 C-lobe contacts the JH2 N-lobe,
with a helix-helix contact between the JH1 C-helix and the
JH2 C-helix. This anti-symmetrical interface has not been
reported in any other kinase/pseudo-kinase pair systems.
In 2005, studies identified the V617F mutation of the
JAK2 JH2 domain in large numbers of patients with
diverse clonal myeloid disorders [14,17,25-33]. The sur-
prising frequency of this mutation suggests that V617 may
play important roles in the auto-regulation of JAK2 and
could become an important molecular target for new drug
design. The V617F findings also imply that other muta-
tions with similar phenotypes might have been ignored in
the past; Ma et al [34] recent confirmed this idea through
clinical evidence documenting mutations in exons 12
through 15 in patients with MPN-related phenotypes.
It has been suggested that the theoretical model outlined
above may be able to explain the mutational effect of
JAK2 V617F at the atomic level [35]. Starting from this
theoretical model, a homology-based structure has been
used to explain the mutational effect of an exon-12
mutant [36]. Homology modelling technique has also
been applied to predict the mutational effect of an exon
12 deletion [36]. Although those models demonstrate the
relative position of V617 to the JH1/JH2 domain, further
atomic level details, not seen in those models, are desper-
ately needed to explain the constitutive activation caused
by V617F.
Molecular dynamics simulations of biomolecules have
provided useful information complementary to experi-
mental evidence [37-39]. We recently reported 60-ns
molecular dynamics simulations of the wild-type and
V617F mutant JAK2 proteins, starting with the theoretical
model mentioned above [23,40]. Although the overall
fold is maintained, the local conformations obtained
from our simulations are significantly different from the
starting theoretical homology model. More importantly,
the simulation results now are able to explain the auto-
regulation of JAK2 and the constitutive activation due to
V617F in detail. There are three key groups of interactions
between the JH1 and JH2 domains, holding JH1 in a
closed inactive conformation. In the V617F mutant, F617
interacts with F595 and blocks other key interactions,
resulting in loss of the JH1/JH2 interactions and forcing
JH1 back to it open, active conformation (Figure 1).
Nevertheless, only the wild-type and one mutant (V617F)
JAK2 were simulated in our previous study, hence the pre-
diction of the JH1/JH2 domain interactions is not yet con-
clusive. Here we extend the simulations to newly
discovered, clinically observed mutants, along with a set
of presumably benign control mutants (Figure 2). Our
findings here unveil the JAK2 auto-regulation mechanism
in much greater detail, and simulation results provide a
plausible explanation for the effects of each mutant at the
atomic level. This study confirms the anti-symmetrical
JH1/JH2 interface and, to our best knowledge, is the first
to reconcile extensive clinically observed mutants through
computational simulations of JAK2. These findings may
provide the framework for rational drug design targeting
various JAK2 mutants.
Results and discussion
JH1/JH2 Interface and Mutant Selection
The JH1/JH2 interface derived from our previous simula-
tion work is summarized in Figure 1. Three key groups of
interactions are shown: I-1 is the helix-helix interactions
between the JH1 C-helix and the JH2 C-helix; I-2 is the
interactions between the JH1 activation loop (A-loop)
and the JH2 C-helix; and I-3 is the interactions between
the activation loop of JH1 and a region of contact in JH2,
including V617.
Ma et al [34] recently reported detection of several muta-
tions in exons 12 to 15, based on analysis of approxi-
mately 20,000 clinical blood samples. Their findings
suggested that molecular testing of JAK2  mutations
should not be restricted to the V617F and exon 12 muta-
tions, but perhaps should extend to most of the JH2
pseudo-kinase domain. Hence, the mutants used in our
simulations were selected from the report of Ma et al (Fig-
ure 2): K539L in exon 12; R564L, L579F, H587N, andBMC Structural Biology 2009, 9:58 http://www.biomedcentral.com/1472-6807/9/58
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The simulation-derived JH1/JH2 interface of JAK2 Figure 1
The simulation-derived JH1/JH2 interface of JAK2. Upper: The overall relative positions of JH1 and JH2. JH1 and JH2 
form an anti-symmetrical pair (dimer). The N- and C- lobes of JH1 and JH2 are shown in different colors and are indicated by 
text with the corresponding color. The circled area is the main region of the JH1/JH2 interface relevant to JAK2 auto-regula-
tion. The red loop is part of the JH1 activation loop (residues 995 to 1005). Lower: A more detailed view of the JH1/JH2 inter-
face. The curved arrow indicates the torsion angle between the C-helices of JH1 and JH2. The blue labels (I-1, I-2, and I-3) 
indicate the sub-interfaces, or groups of interactions, defined in the previous work[42]: I-1, interactions between the C-helices 
of JH1 and JH2; I-2, interactions between the JH1 activation loop and the JH2 C-helix; and I-3, interactions between the JH1 
activation loop and residues near position 617 of JH2.BMC Structural Biology 2009, 9:58 http://www.biomedcentral.com/1472-6807/9/58
Page 4 of 14
(page number not for citation purposes)
S591L in exon 13; 14-del (deletion of entire exon 14, cor-
responding to residues 592 to 622), H606Q, V617I,
V617F, and C618R in exon 14, and L624P in exon 15. All
were detected in patients with MPN. In addition, control
simulations were performed using the K603Q/N667K
double-mutant, V617C, and V617Y. The double-mutant
should be benign because Q603/K667 is found in the
JAK2 of other mammals, including pig, chicken, mouse,
and rat; only human and pony show the "un-mutated"
sequences (K603/N667). V617C and V617Y have never
been reported in patients with MPN, despite the preva-
lence of V617F and experimental data demonstrating that
V617C is benign [41].
Distortions of JH1/JH2 Interactions Due to Various JAK2 
Mutations
Long time (60 ns each) full-scale molecular dynamics
simulations were performed for each mutant, using simu-
lation protocols described previously [42] and in the
Methods section. The simulations performed here require
at least 20 ns to reach steady-state, and the resulting muta-
tional structure changes cannot be obtained by simple
homology modelling methods [36].
The use of various distances between JH1 and JH2 proved
useful in characterizing the JH1/JH2 interface in our pre-
vious work [42]. However, the large number of distances
needed to monitor the JH1/JH2 interface makes a succinct
summary of the results difficult. Hence, instead of inter-
atomic distances, we used the torsion angle between the
C-helices of JH1 and JH2 to monitor the I-1 group of
interactions. Figure 3 shows the relative torsion angle,
defined as the dihedral angle between the carbonyl car-
bon atoms of residues R893, E900, S599, and E592, of all
mutants from simulations,. I-1 interactions are severely
changed in four mutants: K539L, S591L, V617I, and
C618R. The data for 14-del is not shown since this mutant
lacks the entire JH2 C-helix. I-1 interactions are more-or-
less maintained in four mutants: L579F, K603N667K,
V617C, and V617Y.
For I-2 and I-3 the van der Waals contact, a measure of
inter-atomic interaction, was used to quantitatively ana-
lyze the interactions. The following van der Waals con-
tacts were measured:
• vdw(JH1:A, JH2:C): the van der Waals contact between
the JH1 activation-loop (residues 995 to 1005) and the
JH2 C-helix (resides 585 to 595). This term mainly meas-
ures the I-2 interactions.
￿ vdw(JH1:A, JH2:V): the van der Waals contact between
JH1 activation-loop and JH2 residues 614 to 619. This
term mainly measures the I-3 interactions.
Schematic diagram of JAK2 gene and protein showing the homology domains (JH1-7) Figure 2
Schematic diagram of JAK2 gene and protein showing the homology domains (JH1-7). The schematic protein 
shows the distribution of the studied mutations along with the corresponding exons. Mutations depicted in red are control 
mutations and mutations depicted in black have been reported in patients with MPN.BMC Structural Biology 2009, 9:58 http://www.biomedcentral.com/1472-6807/9/58
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￿ vdw(JH1:A, JH2:CV): the summation of the above two
terms, vdw(JH1:A, JH2:C) and vdw (JH1:A, JH2:V). This
term measures the total interactions of I-2 and I-3.
van der Waals contacts usually have negative values, indi-
cating the molecular attracting force between atoms in
molecules. A van der Waals contact larger in magnitude
(with a negative sign) indicates that the two groups of
measured atoms are closer; the van der Waals contact will
be near 0 when two groups of measured atoms are far
away from each other. Hence, the van der Waals contacts
in Figure 4 can be thought of as the measure of the close-
ness between the JH1 activation loop and the JH2 domain
(I-2 and I-3 interactions shown in Figure 1 lower panel).
The total term, vdw(JH1:A, JH2:CV), indicates how much
the JH1 activation loop is "locked" by the JH2 domain.
When the contact is strong, there is no space for ATP or lig-
ands to enter the active site and the JH1 kinase domain is
thus locked and inactive. The results suggest that wild-
type, K603Q/N667K, V617C, and V617I JAK2 have signif-
icantly larger contacts between the JH1 activation loop
and the JH1 domain, while the K539L, R564L, S591L, 14-
del, H606Q, V617F, and C618R mutants have very small
contacts.
Table 1 summarizes the mutational effect annotations
from simulations and confirms that the control mutants
K603Q/N667K and V617C are likely to be benign, as well
as the comparison with experimental/clinical evidence.
This result is consistent with the fact that all mutants
except K603Q/N667K, V617C, and V617Y correspond to
MPN-positive cases. V617C in fact has been shown to be
benign experimentally [41]. In addition, the simulation
results of V617F and K539L suggest that both are deleteri-
ous mutants and cause significant changes in the JH1/JH2
interface, well in line with clinical data showing that both
The relative torsion angle between the JH1 C-helix and the JH2 C-helix Figure 3
The relative torsion angle between the JH1 C-helix and the JH2 C-helix. This angle is defined as the dihedral angle 
between the carbonyl carbon atoms of residues R893, E900, S599, and E592. Data across the bottom of the figure indicate the 
difference in torsion of each mutant relative to the average torsion of the wild-type JAK2 simulation (-5.71 degrees). Mutations 
with larger relative torsion angles exhibit greater deviation from wild-type JAK2 and are thus more likely to be deleterious. 
The error bars are the standard deviations of the calculated values from the last 30-ns trajectory for each mutant. Entries were 
obtained with a sampling frequency of 10 ps; i.e., 3,000 sample data points for each mutant simulation.BMC Structural Biology 2009, 9:58 http://www.biomedcentral.com/1472-6807/9/58
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are transforming [17,43,44]. Hence V617F and K539L can
be considered as the positive control simulations.
Detailed analyses and the origins of the mutation effects
for each mutant will be discussed in the following sec-
tions.
Origins of mutational effects
V617X Mutants
Figure 5 shows representative snapshots for mutations at
the 617 position. In wild-type JAK2, the JH1 activation
loop is in contact with V617 and nearby residues, as well
as the residues of JH2 C-helix, especially F595 and S591.
I-1, I-2, and I-3 interactions are well preserved (Figure 4
and Figure 5). In V617F, F617 interacts with F595 and
hence blocks the contacts between the JH1 activation loop
and the JH2 C-helix. The JH1 activation loop is wide-open
and highly accessible. I-1, I-2, and I-3 interactions are
both lost (Figure 4 and Figure 5). This mutation has been
discussed in detail in our previous study [42].
V617C is very similar to wild-type and all three sets of
interactions (I-1, I-2, and I-3) are well preserved. V617C is
thus a benign mutation, consistent with a recent experi-
mental study [41]. However, close examination of the
local conformation indicates that C617 binds to the JH1
activation loop in a slightly different way. In WT, V617
van der Waals contact energies between different groups for each JAK2 mutant Figure 4
van der Waals contact energies between different groups for each JAK2 mutant. Three sets of van der Waals con-
tact energies were calculated (also see the main text): vdw(JH1:A, JH2:C) is the van der Waals contact between the JH1 activa-
tion-loop (residues 995 to 1005) and the JH2 C-helix (resides 585 to 595), colored white; vdw(JH1:A, JH2:V) is the van der 
Waals contact between the JH1 activation-loop and JH2 residues 614 to 619, colored light gray; and vdw(JH1:A, JH2:CV) rep-
resents the summation of the above two terms, colored dark gray. A larger (magnitude) van der Waals contact indicates a 
stronger interface. Wild-type JAK2 (WT) has the strongest interactions whereas a deleterious mutant, such as 14-del, will have 
very weak interactions. The error bars indicate the standard deviations of the calculated values from the last 30-ns trajectory 
for each mutant. Entries were obtained with a sampling frequency of 10 ps (i.e., 3,000 sample data points for each mutant sim-
ulation).BMC Structural Biology 2009, 9:58 http://www.biomedcentral.com/1472-6807/9/58
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mainly contacts with hydrophobic residues V1000,
L1001, and P1002, while in V617C, C617 slowly moves
to form polar interactions with residues 1003 to 1005
after 40 ns. This implies that while V617C does not cause
constitutive activation, it may induce different phosphor-
ylation patterns at the JH1 activation loop.
V617I is similar to wild-type in that I-2 and I-3 are main-
tained; that is, the JH1 activation loop is locked by the JH2
C-helix and V617 region residues. However, the bulky
side chain of I617 pushes the JH1 activation loop toward
the I-1 interface (JH1 C-helix/JH2 C-helix) and breaks the
I-1 interactions. This may imply that a mutation with a
large non-polar side-chain will yield similar results.
In V617Y (Figure 4 and Figure 5), Y617 also interacts with
F595 and blocks the contacts between the JH1 activation
loop and JH2 C-helix in a way very similar to V617F, in
that the I-2 interactions (vdw [JH1:A, JH2:C]) are severely
damaged. However, while its aromatic ring interacts with
F595, the polar tail of Y617 moves near the interface
between the JH1 C-helix and the JH2 C-helix, forming
multiple hydrogen-bonds with nearby water molecules
and with the JH1 activation loop (not shown), indicated
by the small decrease in the I-3 interactions (vdw [JH1:A,
JH2:V]). The result is that the JH1/JH2 interface is not as
open as with F617. Based on the results of V617F and
V617Y, V617W would have mutational effects similar to
those of V617F, since it will also interact with F595 and
does not have a polar tail like V617Y. This prediction is in
fact consistent with recent observations [41].
The simulation results of V617 mutants demonstrate the
important roles that residue 617 side chain plays in JH1/
JH2 interactions. An aromatic ring side chain (V617F,Y)
interacts with F595 to block the JH1 activation contact; a
polar side chain (V617C) could change the local confor-
mation and form a contact with K1005; and a large hydro-
phobic side chain (V617I) could interfere with the I-1
interactions.
S591
In our previous study, we predicted that a mutation of
S591 would break the polar interaction between S591 and
Q1003 and hence affect the I-1 interactions. S591L was
indeed observed in MPN patients recently [34]. As shown
in Figure 6, S591L has the same conformation as wild-
type JAK2 at the very beginning of simulations (0 ns). At
44 ns, the JH1/JH2 interface is well formed in wild-type
JAK2; in S591L JAK2, L591 forms hydrophobic contacts
with nearby F595, L583, and A586. The I-1 interface is
totally distorted, and the I-2 and I-3 falls apart as well. The
result suggests that S591L will be a severely deleterious
mutation and will cause constitutive activation of JAK2.
The mechanism may reflect the hydrophobic nature of the
L591 residue in that its side chain is repelled by the JH1/
JH2 interface region, which is highly solvent-accessible
and is surrounded with many water molecules.
K539L, C618R, and R564L
In the simulation-derived structure (Figure 1), V617 is
positioned to contact the JH1 activation loop, a result of
the fold of the JH2 domain. A mutation altering the JH2
fold will likely affect the V617 position and hence the
JH1/JH2 interface. V617 is located at the joint of the β-4
and β-5 sheets (Figure 7). These two beta sheets are con-
nected through the hydrogen bonding network and
anchored by surrounding residues. Figure 7 shows parts of
Table 1: Summary of predicted effects of JAK2 mutations.
Mutation Interactions JH1/JH2 interface Openness MPD implication[17,34,43,44] Experimental evidence[41]
I-1 I-2 I-3
Wild-Type O O O O no benign
K539L XX XX X XX yes
R564L X XX X XX yes
L579F O X X X yes
H587N X X X X yes
S591L XX XX X XX yes
14-del XX XX X XX yes
K603QN667K OOO O n o
H606Q X XX X XX yes
V617C O O O O benign
V617F X XX X XX yes deleterious
V617I XX O O XX deleterious
V617Y OXO X
C618R XX XX X XX yes
L624P X X O X yes
Summary of predicted effects of JAK2 mutations on I-1, I-2, and I-3 interactions and total effects on the JH1/JH2 interface; and the comparison with 
experimental/clinical evidence. "O" indicates benign; "X", mildly deleterious; "XX", severely deleterious. The "JH1/JH2 openness" is defined as 
severely deleterious when I-1 or I-2 is severely deleterious.BMC Structural Biology 2009, 9:58 http://www.biomedcentral.com/1472-6807/9/58
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those surrounding residues. A loop from K539 to D544
forms few interactions with the β-4 sheet: D620 is in a
highly charged environment formed by K539 and R541.
C616 and C618, through some water bridges, point to the
charged environment formed by R564, E543, and D544.
Simulation results indicate that mutations of the relevant
residues significantly disrupt the local conformation for
the following reasons (Figure 7):
In K539L, L539 moves away from the highly-charged
region of D620 and R541 and moves E543 and D544
downward.
In R564L, the strong salt bridge interactions between
R564 and E543/D544 are completely lost.
In C618R, R618 moves toward E543/D544 and forms
strong salt bridges with them, disrupting the interaction
between R564 and E543.
These conformational changes are consistent with the
analysis of the JH1/JH2 interface (Figure 1, Figure 3, and
Table 1). The results also suggest that the loop of residues
539 to 544 is important to support the local conformation
near V617.
Possible origins of V617X mutational effects derived from the snapshots of various mutant simulations at 44 ns Figure 5
Possible origins of V617X mutational effects derived from the snapshots of various mutant simulations at 44 
ns. Color codes are the same as in Figure 1. In wild-type JAK2 (WT), the JH1 activation loop is in contact with V617 and nearby 
residues, as well as the residues of the JH2 C-helix (especially F595 and S591). V617C is very similar to WT. All key interactions 
seem to be kept. However, C617 binds to different parts of the JH1 activation loop: it is now close to K1005 rather than 
L1001 and P1002. K1005 is the edge of the red region shown in the figure. V617I is similar to V617C and WT in that I-2 and I-
3 are maintained (i.e., the JH1 activation loop is locked by the JH2 C-helix and residues in the V617 region). However, the 
bulky side chain of I617 pushes the JH1 activation loop toward the I-1 interface (JH1 C-helix/JH2 C-helix) and breaks the I-1 
interactions. In V617F, F617 interacts with F595 and hence blocks the contacts between the JH1 activation loop and the JH2 
C-helix. The JH1 activation loop is wide-open and highly accessible. In V617Y, Y617 also interacts with F595 and blocks the 
contacts between the JH1 activation loop and the JH2 C-helix. However, the polar tail of Y617 moves near the interface 
between the JH1 C-helix and the JH2 C-helix, forming multiple hydrogen-bonds with nearby water molecules and the JH1 acti-
vation loop (not shown). The result is that the JH1/JH2 interface is not as open as in the case of V617F.BMC Structural Biology 2009, 9:58 http://www.biomedcentral.com/1472-6807/9/58
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L579F, L624P, and H606Q
Similarly, L624 is located in the β-5 sheet, L579 is located
in a nearby beta-sheet, and H606Q is in the loop connect-
ing the JH2 C-helix and β-4 sheet (Figure 8). All three
mutants cause conformational changes in this region. In
L579F, F579 interacts with nearby F628, changes the sur-
rounding packing pattern, and causes the conformational
changes between the β-4 and β-5 sheets. In L624P, P624
enforces a conformational change of the β-5 sheet because
of the rigid conformation of proline. L579F and L624P
cause local conformational changes but their mutational
effects are relatively indirect and not as deleterious, con-
sistent with the simulation results (Figure 3, and Figure 4).
H606Q disrupts the interactions between the residue 606
sidechain and the L604/L609 backbones, affecting the
conformation of the loop (604 to 609) connecting the
JH2 C-helix and the β-4 sheet and thus changing the posi-
tion of V617 relative to the C-helix. This finding is consist-
ent with the simulation results in that the I-2 and I-3
interactions are damaged severely (Figure 4) when the I-1
is moderately distorted (Figure 3). In this region, E627
and K688 form strong salt bridge interactions to maintain
the local conformation. Mutations of these two positions
or nearby residues may also result in strong deleterious
effects.
14-del
In this mutant the entire exon-14 coding region is deleted
(residues 593 to 622). Almost every residue of the JH1/
Possible origins of S591L mutational effects derived from the  snapshots of various mutant simulations at 0 and 44 ns Figure 6
Possible origins of S591L mutational effects derived 
from the snapshots of various mutant simulations at 
0 and 44 ns. Color codes are the same as in Figure 1. At 
the very beginning of simulations (0 ns), S591L has the same 
conformation as wild-type JAK2 (WT). At 44 ns, the JH1/JH2 
interface is well formed in WT while L591 forms hydropho-
bic contacts with nearby F595, L583, and A586, totally dis-
rupting the JH1/JH2 interface.
Possible origins of mutational effects of K539L, C618R, and  R564L derived from the snapshots of various mutant simula- tions at 44 ns Figure 7
Possible origins of mutational effects of K539L, 
C618R, and R564L derived from the snapshots of var-
ious mutant simulations at 44 ns. The JH2 C-helix is 
shown in orange, the β-4 sheet in blue, and the β-5 sheet in 
red. In all three cases, the local conformation near V617 is 
distorted, although through different mechanisms. In K539L, 
L539 moves away from the highly-charged region of D620 
and R541 and brings down E543, D544. In R564L, the strong 
interactions between R564 and E543/D544 are totally miss-
ing. In C618R, R618 moves toward E543/D544 and forms 
strong interactions with them.BMC Structural Biology 2009, 9:58 http://www.biomedcentral.com/1472-6807/9/58
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JH2 interface is missing, except S591 and E952. Simula-
tion results (Figure 3 and Figure 4) suggest that this
mutant will very likely cause JAK2 constitutive activation.
H587N and K603Q/N667K Double-Mutant
Because H587 is exposed to solvent and H587N would
constitute a polar-to-polar conserved mutation, this varia-
tion might not be expected to cause a significant muta-
tional effect. However, simulation results indicate that
H587N modifies hydrogen bond pattern of the 587 resi-
due. The sidechain of H587 normally forms hydrogen
bonds with the backbones of Y590 and S591; in the N587
variant, the S591 backbone forms hydrogen bonds with
the backbone of N587 (Figure 9). The altered hydrogen
bond pattern causes rotation of the JH2 C-helix and addi-
tional changes in the pattern of the hydrogen bond net-
work between E890, R588, and N589. In N587, E890 now
forms a new hydrogen bond with E589 and brings itself
closer to the JH2 C-helix. The result is the disruption of
the I-1 interactions, indicating that H587N is a deleterious
mutation.
As mentioned above, the K603Q/N667K double-mutant
exists in the JAK2s of other mammals, including pig,
chicken, mouse, and rat; only human and pony sequences
show the "un-mutated" sequences (K603/N667). Not sur-
prisingly, the simulation results suggest that K603/N667
will be a benign mutation (Figure 3, Figure 4, and Table
1). However, the detailed I-1 interaction patterns are sig-
nificantly different from those of wild-type JAK2 (Figure
9). Wild-type has the following hydrogen bonding or salt
bridge pairs: K603/E900, E596/E896, E596/R893, E592/
R588, and R588/E890. In K603Q/N667K, there is no salt
bridge between Q603 and E900, since Q603 lacks a posi-
tive charge; Q603 forms a hydrogen bond with S904
instead, causing significant rearrangements of the interac-
tions. Hydrogen bonding or salt bridge pairs in K603/
QN667K JAK2 include Q603/S904, E596/R893, E896/
R893, E900/R893, E592/R897, and R588/E890. The inter-
actions in K603Q/N667K JAK2 seem stronger than in
wild-type. Indeed, the fluctuation (standard deviation) of
the torsion angle between JH1/JH2 C-helices is much
smaller in K603Q/N667K than in wild-type (Figure 3).
This finding suggests that K603Q/N667K could have
more stable I-1 interactions and may imply that muta-
tional studies based on murine models could lead to dif-
ferent results, especially when considering the effect on
the I-1 interactions. For example, H587 is no longer held
by the side chains of Y590 and S591 in K603Q/N667K,
which may imply that a mutation at the 587 position,
such as H587N, would have different effect in the K603Q/
N667K mutant than in wild-type JAK2.
Conclusion
In summary, we report a set of molecular dynamics simu-
lations on clinically observed mutants along with control
mutants. The results, which could not be obtained from
simple homology-based models or other static structures,
are consistent with available clinical and experimental
evidence. Although the JH1/JH2 interface is derived from
simulations and should be considered as putative, the
anti-symmetrical JH1/JH2 interface seems very reasonable
and we are able to explain the mutational effect for each
mutant at atomic levels, including the presumably benign
mutants V617C and K603Q/N667K. The results and anal-
ysis provide likely structural explanations of mutational
mechanisms and may advance the understanding of JAK2
auto-regulation. It is clear that our simulation-derived
structures are capable of reproducing all available experi-
Possible origins of mutational effects of L579F, L624P, and  H606Q derived from the snapshots of various mutant simu- lations at 44 ns Figure 8
Possible origins of mutational effects of L579F, 
L624P, and H606Q derived from the snapshots of 
various mutant simulations at 44 ns. The JH2 C-helix is 
shown in orange, the β-4 sheet in blue, and the β-5 sheet in 
red. In L579F, F579 interacts with nearby F628, changes the 
surrounding packing pattern, and causes conformational 
changes between the β-4 and β-5 sheets. In L624P, P624 
enforces a conformational change of the β-5 sheet. In 
H606Q, the interactions between the H606 side chain and 
the L604/L609 backbones are disrupted and the conforma-
tion of the loop (604 to 609) is changed.BMC Structural Biology 2009, 9:58 http://www.biomedcentral.com/1472-6807/9/58
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mental/clinical mutational data. However, it is important
to emphasize that such success does not prove that these
structures are correct before experimental structures are
available.
Our simulation findings together with recent JAK2 muta-
tion profiling results [34] suggest that molecular testing of
JAK2 mutations should not be restricted to V617F and
exon 12 mutations [43-45], but perhaps should extend to
most of the pseudo-kinase domain coding region as well,
especially the relevant residues shown in our atomic-level
analysis.
Methods
Starting Structure
The only currently available theoretical structure model of
the entire JAK2 protein, built using homology modeling
methods, and co-evolution data [23,40], were used as the
starting point. The original papers of this model have
been cited over 30 times and have been extensively used
to rationalize experimental/clinical evidence. Although it
is relatively old, it is widely accepted in the JAK2 commu-
nity[35], and has been utilized to explain structural effects
[36,46], and has even been used as the starting model for
other system (JAK1)[47]. The domain arrangement of this
model is the current consensus accepted by those who are
working on JAK2 crystal structures [48]. The inter-domain
interaction between JH1 and JH2 was further verified by
the DComplex server http://sparks.informatics.iupui.edu/
czhang/complex.html and the reported binding free
energy[49] between JH1 (residues 840 to 1129) and JH2
(residues 543 to 839) is -11.21 Kcal/mol for this homol-
ogy model; while the value for the MD-simulation struc-
ture at 44 ns snapshot (WT) is -12.84 Kcal/mol. Both
show that the JH1/JH2 inter-domain arrangement is rea-
sonable. Based on the above reasons, we chose this model
as our starting structure for all subsequent simulations.
Homology Modelling for 14-del
The MODELLER software package (version 9v5) [50] was
used to build the homology model for the 14-del variant;
The sequences of 14-del JAK2 (deletion of residues S593
to N622) and wild-type JAK2 proteins were aligned using
the ClustalW web server http://www.ebi.ac.uk/Tools/clus
talw/index.html[51], resulting in a 30-residue gap
between residue 592 and 623 (WT numbering). The
aligned WT and 14-del sequences were used as the input
alignment for MODELLER, and the WT structure men-
tioned above as the template structure. The model-
ler.automodel module in MODELLER with default
parameters was used to build one model without any
additional restraints. This MODELLER-generated 14-del
structure then was used as the starting structure for the
subsequent MD simulation of the 14-del variant.
Molecular Dynamics Simulations
The homology-based model of the whole JAK2 assembly
[40] was used as the initial structure for the wild-type and
all mutant simulations, except for the 14-del mutant as
described in the previous section. The following prepara-
tion steps were performed prior to molecular dynamics
simulations, using the VMD software package (version
1.8.6, http://www.ks.uiuc.edu/Research/vmd/)[52]. All
ionizable residues were considered in the standard ioniza-
tion state at neutral pH condition. The whole protein then
Possible origins of mutational effects of H587N and the dou- ble mutant K603Q/N667K, derived from the snapshots of  various mutant simulations at 44 ns Figure 9
Possible origins of mutational effects of H587N and 
the double mutant K603Q/N667K, derived from the 
snapshots of various mutant simulations at 44 ns. The 
JH2 C helix is shown in orange and the JH1 C-helix is shown 
in pink. The H587 side chain forms hydrogen bonds with the 
Y590 backbone and the S591 backbone. In N587, the hydro-
gen bond network is modified. The S591 backbone now 
forms a hydrogen bond with the N587 backbone. The 
changes in hydrogen bond pattern result in a rotation of the 
JH2 C-helix (indicated by the yellow) as well as changes of 
the pattern of the hydrogen bond network between E890, 
R588, and N589. In K603Q/N667K, a control mutant, the 
JH1/JH2 interface seems to be maintained but the hydrogen 
bond network is significantly different from that of the wild-
type.BMC Structural Biology 2009, 9:58 http://www.biomedcentral.com/1472-6807/9/58
Page 12 of 14
(page number not for citation purposes)
was put in a water box, filled with TIP3P water[53], with
at least 15 Å buffer distance in any direction, resulting in
a roughly 130 Å × 120 Å × 90 Å box containing JAK2 and
water molecules. Sodium and chloride ions were added
randomly in space (but were kept initially at least 4.7 Å
away from any solute atoms) to reach the physiological
concentration of sodium ions (0.14 M) and overall elec-
tric neutrality. The complex was oriented to align its long-
est axis with the x-axis of the water box, and its center of
mass was placed at the center of the box. Water molecules
less than 1.4 Å from any atom of the complex were
removed. The resulting system contained 138,824 atoms
for the wild-type (JAK2:17,657; water: 121,062; sodium
ion: 53; chloride ion: 52) and 130,007 atoms for the 14-
del mutant (JAK2:17,209; water: 112,698; sodium ion:
49; chloride ion: 49).
All molecular dynamics (MD) simulations were per-
formed using the NAMD package (version 2.6) [54] with
the CHARMM27 force field [55,56]. Default parameters
and settings were used except as mentioned below. Peri-
odic boundary conditions were used along with the iso-
thermal-isobaric ensemble (NPT) at 1 atm and 298 K
using an extended system pressure algorithm [57] with
effective mass of 500.0 amu and Nosé-Hoover thermo-
stat[58,59] with effective mass of 1000.0 kcal/mol-ps2.
The smooth particle mesh Ewald (PME) method [60] was
employed. A B-spline interpolation order of 4 was used,
combined with 120, 120, and 75 FFT grid points for the
lattice directions x, y, and z, respectively. Non-bonded
interactions were treated using an atom-based cutoff of 12
Å with switching van der Waals potential beginning at 10
Å. Numerical integration was performed using the leap-
frog Verlet algorithm with 1 fs time step. Covalent bond
lengths involving hydrogen were constrained using the
SHAKE algorithm [61,62].
The following procedure was used prior to the data collec-
tion for the wild-type and 14-del mutant. All atoms of the
protein complex were first restrained at their starting
structure positions with a force constant of 50 kcal/mol/
Å2. Water and ion molecules were first energy-optimized
and then underwent the following simulation annealing
to ensure the proper equilibration. The temperature was
increased from 0 K to 600 K at the rate of 1 K per ps and
maintained at 600 K for 500 ps. Then the temperature was
decreased to 300 K at the rate of 1 K per ps and maintained
at 300 K for 500 ps. The system then was kept at 300 K for
4 ns. The total equilibration time was about 5 ns in this
step. The system was next brought down to 0 K and the
same 5 ns equilibration was repeated, resulting in an equi-
libration simulation of total 10 ns for water molecules
and ions. The water/ion-equilibrated systems, both of the
wild-type and 14-del, then were used as the starting point
for the production simulations. All mutants, except 14-
del, were created from the water/ion-equilibrated wild-
type structure through the VMD package. For all simula-
tions, the restraint force constant then was gradually
reduced to 3 kcal/mole/Å2 during a 500-ps period, fol-
lowed by 2,000-step energy-minimization for all atoms
and a 300-ps heating period with the temperature
increased from 0 to 300 K at the rate of 1 K per ps. Produc-
tion MD simulations of 60 ns were then performed for all
simulations without any constraint or restraint. Trajecto-
ries were saved at the frequency of 1 ps.
Simulation Stability
Figure 10 shows the heavy atom root-mean-squared devi-
ation (RMSD, in Å, relative to the initial strucuture) of JH1
domain (defined as residue 840 to 1129), JH2 domain
(defined as residue 543 to 839), and of JH1/JH2 together
(defined as residue 543 to 1129) for the wild-type JAK2.
RMSD is commonly used as an indicator of stability of
MD simulations. The RMSD curves of individual JH1 and
JH2 domains indicate simulations of both domains are
stable after ~20 ns. The RMSD curve of combined JH1/
JH2 indicates that the relative positions of JH1/JH2 as well
as their tertiary interactions are also stable after ~20 ns.
Simulations of other mutants exhibit similar behaviours.
Those results suggest that the simulations reported here
are converged and the corresponding derived analysis is
reliable in the timescale simulated.
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